Resultados de Búsqueda
It's recommended offering transoral laser microsurgery to people with newly‑diagnosed T1a squamous cell carcinoma of the glottic larynx.
NICE
National Institute for Health and Clinical Excellence (NICE)
Offer a choice of transoral laser microsurgery or radiotherapy to people with newly‑diagnosed T1b–T2 squamous cell carcinoma of the glottic larynx. Offer a choice of transoral surgery or radiotherapy to people with newly‑diagnosed T1–T2 squamous cell carcinoma of the supraglottic larynx.
ver más ... 2018It's recommended by current evidence on the safety of low-level laser therapy for oral mucositis as it shows no major safety concerns. Evidence on efficacy is adequate in quality and quantity. ...
NICE
National Institute for Health and Clinical Excellence (NICE)
No further information.
ver más ... 2018The PleurX peritoneal catheter drainage system in the NHS is recommended by the evidence. The available clinical evidence suggests that the PleurX peritoneal catheter drainage system is clinically ...
NICE
National Institute for Health and Clinical Excellence (NICE)
The PleurX peritoneal catheter drainage system should be considered for use in patients with treatment-resistant, recurrent malignant ascites. The PleurX peritoneal catheter drainage system is associated with an estimated cost saving of £1,051 per patient when compared with inpatient large-volume paracentesis.
ver más ... 2018The Dynamic Spectral Imaging System (DYSIS) colposcope with DYSISmap shows promise and is recommended for assessing suspected cervical abnormalities in people having colposcopy. Centres using ...
NICE
National Institute for Health and Clinical Excellence (NICE)
Further research is recommended on the effects of using the DYSIS colposcope with DYSISmap on clinical and patient outcomes in a human papilloma virus primary screening setting, and on patient experience (see sections 6.1 to 6.3). The ZedScan I shows promise in assessing suspected cervical abnormalities, but there is currently not enough evidence to recommend its routine adoption. Further research on the effects of using the technology on clinical and patient outcomes is recommended (see ...
ver más ... 2018Eribulin is not recommended for treating locally advanced or metastatic breast cancer in adults who have had only 1 chemotherapy regimen
NICE
National Institute for Health and Clinical Excellence (NICE)
This guidance is not intended to affect treatment with eribulin that was started in the NHS before this guidance was published. People having treatment outside this recommendation may continue without change to the funding arrangements in place for them before this guidance was published, until they and their NHS clinician consider it appropriate to stop. People with advanced breast cancer who have had 1 chemotherapy regimen are usually then offered an anthracycline, a taxane or capecitabine, ...
ver más ... 2018